|
1.
|
Gogas HJ, Kirkwood JM and Sondak VK:
Chemotherapy for metastatic melanoma: time for a change? Cancer.
109:455–464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Frame MC: Newest findings on the oldest
oncogene; how activated src does it. J Cell Sci. 117:989–998. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Homsi J, Cubitt C and Daud A: The Src
signaling pathway: a potential target in melanoma and other
malignancies. Expert Opin Ther Targets. 11:91–100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Homsi J, Cubitt CL, Zhang S, Munster PN,
Yu H, Sullivan DM, Jove R, Messina JL and Daud AI: Src activation
in melanoma and Src inhibitors as therapeutic agents in melanoma.
Melanoma Res. 19:167–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Lombardo LJ, Lee FY, Chen P, Norris D,
Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM,
Fairchild C, et al: Discovery of N-(2-chloro-6-methyl-
phenyl)-2-(6-(4-(2-hydroxyethyl)-
piperazin-1-yl)-2-methylpyrimidin-4- ylamino)
thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase
inhibitor with potent antitumor activity in preclinical assays. J
Med Chem. 47:6658–6661. 2004. View Article : Google Scholar
|
|
6.
|
Steinberg M: Dasatinib: a tyrosine kinase
inhibitor for the treatment of chronic myelogenous leukemia and
philadelphia chromosome-positive acute lymphoblastic leukemia. Clin
Ther. 29:2289–2308. 2007. View Article : Google Scholar
|
|
7.
|
Talpaz M, Shah NP, Kantarjian H, Donato N,
Nicoll J, Paquette R, Cortes J, O’Brien S, Nicaise C, Bleickardt E,
Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP and
Sawyers CL: Dasatinib in imatinib-resistant Philadelphia
chromosome-positive leukemias. N Engl J Med. 354:2531–2541. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Finn RS, Dering J, Ginther C, Wilson CA,
Glaspy P, Tchekmedyian N and Slamon DJ: Dasatinib, an orally active
small molecule inhibitor of both the src and abl kinases,
selectively inhibits growth of basal-type/‘triple-negative’ breast
cancer cell lines growing in vitro. Breast Cancer Res Treat.
105:319–326. 2007.PubMed/NCBI
|
|
9.
|
Pichot CS, Hartig SM, Xia L, Arvanitis C,
Monisvais D, Lee FY, Frost JA and Corey SJ: Dasatinib synergizes
with doxorubicin to block growth, migration, and invasion of breast
cancer cells. Br J Cancer. 101:38–47. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Nautiyal J, Majumder P, Patel BB, Lee FY
and Majumdar AP: Src inhibitor dasatinib inhibits growth of breast
cancer cells by modulating EGFR signaling. Cancer Lett.
283:143–151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Okamoto W, Okamoto I, Yoshida T, Okamoto
K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara
K, Fukuoka M, Nishio K and Nakagawa K: Identification of c-Src as a
potential therapeutic target for gastric cancer and of MET
activation as a cause of resistance to c-Src inhibition. Mol Cancer
Ther. 9:1188–1197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Nagaraj NS, Smith JJ, Revetta F,
Washington MK and Merchant NB: Targeted inhibition of SRC kinase
signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther.
9:2322–2332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Johnson FM, Saigal B, Talpaz M and Donato
NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses
invasion and induces cell cycle arrest and apoptosis of head and
neck squamous cell carcinoma and non-small cell lung cancer cells.
Clin Cancer Res. 11:6924–6932. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Guerrouahen BS, Futami M, Vaklavas C,
Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson
LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE and Corey SJ:
Dasatinib inhibits the growth of molecularly heterogeneous myeloid
leukemias. Clin Cancer Res. 16:1149–1158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Eustace AJ, Crown J, Clynes M and
O’Donovan N: Preclinical evaluation of dasatinib, a potent Src
kinase inhibitor, in melanoma cell lines. J Transl Med. 6:532008.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Buettner R, Mesa T, Vultur A, Lee F and
Jove R: Inhibition of Src family kinases with dasatinib blocks
migration and invasion of human melanoma cells. Mol Cancer Res.
6:1766–1774. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kluger HM, Dudek AZ, McCann C, Ritacco J,
Southard N, Jilaveanu LB, Molinaro A and Sznol M: A phase 2 trial
of dasatinib in advanced melanoma. Cancer. 117:2202–2208. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Goding CR: Mitf from neural crest to
melanoma: signal transduction and transcription in the melanocyte
lineage. Genes Dev. 14:1712–1728. 2000.PubMed/NCBI
|
|
19.
|
Reddy KB, Nabha SM and Atanaskova N: Role
of MAP kinase in tumor progression and invasion. Cancer Metastasis
Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Maat W, el Filali M, Dirks-Mulder A,
Luyten GP, Gruis NA, Desjardins L, Boender P, Jager MJ and van der
Velden PA: Episodic Src activation in uveal melanoma revealed by
kinase activity profiling. Br J Cancer. 101:312–319. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Busca R, Bertolotto C, Abbe P, Englaro W,
Ishizaki T, Narumiya S, Boquet P, Ortonne JP and Ballotti R:
Inhibition of Rho is required for cAMP-induced melanoma cell
differentiation. Mol Biol Cell. 9:1367–1378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Folkman J and Moscona A: Role of cell
shape in growth control. Nature. 273:345–349. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Aplin AE and Juliano RL: Integrin and
cytoskeletal regulation of growth factor signaling to the MAP
kinase pathway. J Cell Sci. 112:695–706. 1999.PubMed/NCBI
|
|
24.
|
Schmid-Alliana A, Menou L, Manie S,
Schmid-Antomarchi H, Millet MA, Giuriato S, Ferrua B and Rossi B:
Microtubule integrity regulates src-like and extracellular
signal-regulated kinase activities in human pro-monocytic cells.
Importance for interleukin-1 production. J Biol Chem.
273:3394–3400. 1998. View Article : Google Scholar
|
|
25.
|
Irigoyen JP, Besser D and Nagamine Y:
Cytoskeleton reorganization induces the urokinase-type plasminogen
activator gene via the Ras/extracellular signal-regulated kinase
(ERK) signaling pathway. J Biol Chem. 272:1904–1909. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Rijken PJ, van Hal GJ, van der Heyden MA,
Verkleij AJ and Boonstra J: Actin polymerization is required for
negative feedback regulation of epidermal growth factor-induced
signal transduction. Exp Cell Res. 243:254–262. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Brunet A, Roux D, Lenormand P, Dowd S,
Keyse S and Pouyssegur J: Nuclear translocation of p42/p44
mitogen-activated protein kinase is required for growth
factor-induced gene expression and cell cycle entry. EMBO J.
18:664–674. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Alesiani D, Cicconi R, Mattei M, Bei R and
Canini A: Inhibition of Mek 1/2 kinase activity and stimulation of
melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells.
Int J Oncol. 34:1727–1735. 2009.PubMed/NCBI
|
|
29.
|
Samarakoon R and Higgins PJ: Pp60c-src
mediates ERK activation/nuclear localization and PAI-1 gene
expression in response to cellular deformation. J Cell Physiol.
195:411–420. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Riley D, Carragher NO, Frame MC and Wyke
JA: The mechanism of cell cycle regulation by v-Src. Oncogene.
20:5941–5950. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Carothers Carraway CA, Fang H, Ye XH,
Juang SH, Liu YC, Carvajal ME and Carraway KL:
Membrane-microfilament interactions in ascites tumor cell
microvilli. Identification and isolation of a large
microfilament-associated membrane glycoprotein complex. J Biol
Chem. 266:16238–16246. 1991.
|
|
32.
|
Carraway CA, Carvajal ME and Carraway KL:
Association of the Ras to mitogen-activated protein kinase signal
transduction pathway with microfilaments. Evidence for a
p185(neu)-containing cell surface signal transduction particle
linking the mitogenic pathway to a membrane-microfilament
association site. J Biol Chem. 274:25659–25667. 1999.
|
|
33.
|
Fincham VJ, Chudleigh A and Frame MC:
Regulation of p190 Rho-GAP by v-Src is linked to cytoskeletal
disruption during transformation. J Cell Sci. 112:947–956.
1999.PubMed/NCBI
|
|
34.
|
Smith ER, Smedberg JL, Rula ME, Hamilton
TC and Xu XX: Disassociation of MAPK activation and c-Fos
expression in F9 embryonic carcinoma cells following retinoic
acid-induced endoderm differentiation. J Biol Chem.
276:32094–32100. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Borriello A, Caldarelli I, Basile MA,
Bencivenga D, Tramontano A, Perrotta S, Della RF and Oliva A: The
tyrosine kinase inhibitor dasatinib induces a marked adipogenic
differentiation of human multipotent mesenchymal stromal cells.
PLoS One. 6:e285552011. View Article : Google Scholar
|
|
36.
|
Mazharian A, Ghevaert C, Zhang L, Massberg
S and Watson SP: Dasatinib enhances megakaryocyte differentiation
but inhibits platelet formation. Blood. 117:5198–5206. 2011.
View Article : Google Scholar : PubMed/NCBI
|
